Final phase clinical trial of AstraZeneca COVID-19 vaccine begins in U.S.


  • World
  • Wednesday, 02 Sep 2020

WASHINGTON, Sept. 1 (Xinhua) -- A multi-site, Phase 3 clinical trial evaluating an investigational COVID-19 vaccine known as AZD1222 has begun, the U.S. National Institutes of Health (NIH) announced on Monday.

The trial will enroll approximately 30,000 adult volunteers at 80 sites in the United States to evaluate if the candidate vaccine can prevent COVID-19.

Participants will be randomly assigned to the investigational vaccine group or the placebo group, and neither the investigators nor the participants will know who is assigned to which group.

After an initial screening, participants will receive two injections of either the investigational vaccine or a saline placebo approximately four weeks apart.

One person will receive a placebo injection for every two people who receive AZD1222, which will result in approximately 20,000 people receiving the investigational vaccine and 10,000 people receiving a placebo.

The trial primarily is designed to determine if AZD1222 can prevent symptomatic COVID-19 after two doses.

The United Kingdom-based global biopharmaceutical company AstraZeneca is leading the trial as regulatory sponsor. The National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, and the Biomedical Advanced Research and Development Authority are providing funding support for the trial.

The vaccine candidate uses a non-replicating chimpanzee adenovirus to deliver a SARS-CoV-2 spike protein to induce an immune response, said the NIH.

Article type: metered
User Type: anonymous web
User Status:
Campaign ID: 1
Cxense type: free
User access status: 3
   

Did you find this article insightful?

Yes
No

100% readers found this article insightful

Next In World

COVID-19 vaccine delays may slow wider Irish roll-out, says PM
Poland appeals to Britain to repatriate man in vegetative state
Saudi Arabia expects 'excellent relations' with Biden administration
Larry King, decades-long fixture of U.S. TV interviews, dead at 87
Veteran TV talk show host Larry King dies
Iran's Zarif open to oil, Gulf security contacts with U.S., not on Israel
French health body recommends delaying second COVID shot to six weeks after first
Police detain ally of Kremlin critic Navalny at Moscow rally
Taiwan reports large incursion by Chinese air force
Wife stabs husband after seeing her younger self in old photos, thought he was cheating

Stories You'll Enjoy